Pathogenic variants in
The prevalence of renal involvement in patients with primary mitochondrial disorders has been estimated to range from 25% to 50% (6). The most common renal phenotype in these patients is proximal tubulopathy with or without complete Fanconi syndrome, but a spectrum of manifestations has been described as well, including chronic kidney disease (CKD), distal tubular defects, focal segmental glomerulosclerosis, steroid resistant nephrotic syndrome, renal cysts, nephrocalcinosis and others (6,7,8). However, kidney impairment has been documented in only seven COXPD21 patients, presenting with distal renal tubular acidosis (2,4). A progress into chronic kidney disease (CKD) occurred in one patient at 17 years of age (4). Herein, we report the first COXPD21 patient with generalized tubular dysfunction and early childhood progression to CKD.
The patient is the first child of non-consanguineous parents (father has hypothyroidism and mother was treated for anxiety disorder), born from an uneventful pregnancy. Birth weight was 4.2 kg, and the perinatal period was normal. In early infancy, poor weight gain was observed. Thorough diagnostic evaluation was initiated at six months of age due to failure to thrive, muscular hypotonia, motor delay and recurrent bronchiolitis. The laboratory analyses revealed hyperlactatemia (2.53 mmol/l), hypokalaemia (2.8 mmol/l), absence of other electrolyte abnormalities in serum (table 1) and tubular loss of potassium and magnesium (table 2). The aldosterone level was normal. Serum creatine level and estimated glomerular filtration rates were normal at the time of the first evaluation. The ultrasound exam showed hyperechoic, normal sized kidneys.
Key laboratory findings in serum/plasma over the course of the disease in a patient with COXPD21
Blood gases | ||||
pH | 7.4 | 7.39 | 7.42 | 7.35–7.45 |
HCO3m mmol/L | 20.0 | 16.4 | 24.2 | 21–28 |
Base excess, mmol/L | −4.5 | −8.5 | −0.2 | −2−+3 |
Biochemistry | ||||
Serum creatinine, mcmol/L | 24 | 111 | 274 | 23–37 |
GFR*, ml/min | 116.4 | 32 | 17 | ≥90 |
Cystatin C, mg/L | 1.16 | 2.22 | 4.5 | 0.62–1.2 |
Urea, mmol/L | 4.9 | 15.0 | 35.0 | 3.3–7.5 |
Uric acid, mcmol/L | 272 | 238 | 148 | 120–320 |
Potassium, mmol/L | 2.8 | 6.8 | 5.8 | 3.4–4.7 |
Sodium, mmol/L | 136 | 121 | 146 | 136–148 |
Calcium, mmol/L | 2.71 | 2.27 | 2.38 | 2.05–2.74 |
Magnesium, mmol/L | 0.88 | 0.67 | 0.90 | 0.7–1.05 |
Phosphorus, mmol/L | 2.2 | 0.96 | 2.88 | 1.05–1.80 |
Lactate, mmol/L | 2.53 | 2.15 | 2.0 | 0.2–2.0 |
Hormonal status | ||||
Parathyroid hormone, pg/mL | 26.3 | 3.3 | 17.5 | 15.8–68.3 |
25-hydroxyitamin D, nmol/L | 47.8 | 58.9 | 18.0 | 75.0–250.0 |
Thyroid stimulating hormone, mIU/L | 1.06 | 3.58 | 9.17 | 0.35–4.94 |
Free T4, pmol/L | 16.63 | 12.7 | 8.98 | 9.0–19.0 |
GFR – glomerular filtration rate
After discharge he was lost to follow-up until two years of age when he was readmitted with an elevated creatinine level, reduced estimated glomerular filtrate rate, normochromic anaemia, metabolic acidosis and hyperkalaemia. Urine abnormalities pointed to tubular dysfunction (table 2). Aldosterone, renin and cortisol concentrations were within normal range, while decreased plasma concentration of parathyroid hormone (PTH) was accompanied by normal calcemia.
Results of urinary analyses over the course of the disease in a patient with COXPD21
pH | 6.0 | 6.5 | 6.5 | 5–8 |
Urine- Specific gravity | 1010 | 1010 | 1005 | 1010–1030 |
Urine protein, g/L | <0.1 | <0.1 | <0.1 | <0.1 |
Urine glucose, mmol/L | Negative | Negative | 5.5 | Negative |
Urine blood, RBC/uL | Negative | Negative | Negative | Negative |
Urine white blood cells | Negative | Negative | Negative | Negative |
Protein/Cr, mg/mmoL | 20 | 30 | 52 | <50 |
Aminoaciduria | Negative | Negative | Generalized | Negative |
Beta-2 microglobulin/Cr, mg/mmoL | 0.14 | 0.34 | 26.0 | <0.35 |
Calcium/Cr, mmol/mmol | 0.26 | 0.21 | 1.64 | * |
Uric acid/Cr, mmol/mmol | 1.4 | 0.35 | 0.08 | * |
FeNa, % | 0.8 | 3.1 | 32 | <1 |
FeMg, % | 6.65 | 4.98 | 38.4 | <4 |
TTKG | 9 | 3 | 2 | 4–6* |
TRP, % | 93.8 | 81.2 | 45 | 85–95 |
TmP/GFR, mmol/L | 1.41 | 1.64 | 0.78 | 1.13–1.88 |
Cr – creatinine
FeNa – Fractional excretion of sodium
FeMg – Fractional excretion of magnesium
*TTKG – trans-tubular gradient of potassium (>4% suggests kidney losses in hypokalaemic patient; <7% indicate hypoaldosteronism in hyperkalaemia)
TRP – tubular reabsorption of phosphate
TmP/GFR - tubular maximum phosphate reabsorption per glomerular filtration rate
*Ca/Cr, mmol/mmol - (< 2.2 for <12 months; <1.5 for 1 to 3 years; <1.1 for 3 to 5 years)
*Uric acid/Cr, mmol/mmol - (1.5 for < 1 years; 1.3 for 1 to 3 years; 1.0 for 3 to 5 years)
The association of chronic renal disease with developmental delay of unknown aetiology prompted genetic testing. Two novel heterozygous variants in the
Treatment during the disease included dietary modification, erythropoietin, calcitriol, ion-exchange resin, a “mitochondrial cocktail” of supplements and vitamins, and antiseizure medication. Thyroxine supplementation was introduced in response to hypothyroidism, detected at 4 years of age during a regular follow-up visit. Dosage of thyroxine had to be adjusted over time due to the worsening of thyroid function. Currently, at 4.5 years of age, the boy weighs 11 kg (below 3 standard deviations), has severe motor and verbal delay, and end stage CKD with generalized tubulopathy. We referred the patient to another paediatric centre that provides renal replacement therapy. The dynamics of the serum/plasma and urine laboratory findings during the course of the disease is presented in table 1 and table 2.
The clinical presentations of the patients we have reported on so far are mostly in accordance with other cases of COXPD21 (1,2,3,4,5.) The key clinical features of this particular mitochondrial disorder (failure to thrive, development delay, muscle tone abnormalities, epilepsy) are all present in our patient. A spectrum of brain MRI changes has been described in patients with COXPD21. Therefore, our patient’s brain MRI scan revealed basal ganglia hyper intensity and generalized atrophy, resembling some of the more extensive findings thus reported (2,5).
Our report focusses on the renal aspect of a patient’s phenotype, since the kidney’s involvement in COXPD21 has been described in seven cases so far (2,4). In one of the reports, the male patient of Syrian descent presented with renal tubular acidosis, diagnosed at 6 months of age along with delayed psychomotor development (4). Nephrocalcinosis was observed at 12 months of age. In his early teenage years, the ultrasound showed small and scarred kidneys; the same patient was diagnosed stage III of CKD at 17 years of age. In the largest case series of COXPD21, a third of the patients had distal renal tubular acidosis (2). According to the data, none of them developed chronic kidney disease, despite half of them being of adult age. In contrast to previously reported patients, CKD was already present at two years of age and progressed into the end stage by the age of four. Moreover, the observed generalized tubulopathy differs our patient from COXPD21 patients with isolated renal tubular acidosis as the main tubular dysfunction. However, we can speculate that the origin of tubulopathy stems both from primary mitochondrial disorder and from advanced CKD itself.
Defects in the mitochondrial oxidative phosphorylation system are well-known genetic causes of renal dysfunction. Even though renal impairment can be the presenting feature of mitochondrial diseases, it is more commonly seen after the onset of neurological manifestations (9). Renal impairment can occur at any age in patients with mitochondrial disease, but the median age of this specific organ involvement has been estimated at 12 years (6). Typically, laboratory abnormalities of urine detected during regular patient check-ups are the first sign of kidney involvement in these patients. In our patient, at the very early age of six months, tubular loss of potassium and magnesium was verified. This indicated potential dysfunction of either thick ascending limb of the loop of Henle or distal tubule, even before the rise of urinary beta-2 microglobulin. Initially, there were no signs of proximal tubular dysfunction. Impairment of renal function was verified at two years of age in our patient and was consistent with both proximal and distal tubular dysfunctions. Full expression of Fanconi syndrome has been previously associated with mtDNA deletion syndromes, but also with diseases caused by nuclear DNA mutations affecting mitochondrial functioning (6,10). The presence of glycosuria, hyperphosphaturia, generalized aminoaciduria and low-molecular-weight proteinuria in our patient was detected at the end stage of CKD.
The progression of chronic kidney disease in our patient seemed to be facilitated during severe metabolic crisis occurring at the age of 2.5 years. Impairment of both proximal and distal renal tubules has been designated as generalized tubulopathy and described as such in several patients with mitochondriopathies (6). Interestingly, severe tubular dysfunction has been associated mostly with large mtDNA deletions, thereby contrasting to our patient’s disease, caused by the autosomal-recessive mutations in nuclear
The genotype of our patient includes two variants of unknown significance in
The presence of hypothyroidism in our patient has been demonstrated by elevated thyroid stimulating hormone level and low free thyroxine in blood. A neonatal screening test for congenital hypothyroidism was previously negative. The level of thyroid peroxidase antibodies remained low, suggesting that the occurrence of hypothyroidism is most probably the part of the multisystem presentation of mitochondrial disease. Endocrine abnormalities represent one of the more prominent clinical features of mitochondrial diseases with hypothyroidism being present in approximately 6.3% of patients (13). Interestingly, defects in nuclear genes encoding mitochondrial protein pose a lower risk for hypothyroidism, when compared to mtDNA mutations (2.9% and 8.5%, respectively). The findings of the WES did not reveal any other genetic variant that could be causative to hypothyroidism. Hypothyroidism in the father is caused by Hashimoto thyroiditis and is most probably not related to the hypothyroidism in the proband. Subnormal levels of PTH found in context of overt CKD suggest hypoparathyroidism in our patient. Insufficiency of parathyroid secretion has been well established occurrence in mitochondrial disorders (14), but not in COXPD321 so far (2,3).
The overall clinical course in the patient we report on corresponds well to the previously reported cases of